Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 500 RUTHERFORD AVENUE, 3RD FLOOR CHARLESTOWN MA 02129 |
Tel: | N/A |
Website: | https://www.solidbio.com |
IR: | See website |
Key People | ||
Ian F. Smith Executive Chairman of the Board | Alexander Cumbo President, Chief Executive Officer, Director | Ilan Ganot Co-Founder, Director |
Kevin Tan Chief Financial Officer, Treasurer | Paul Herzich Chief Technology Officer | David Tyronne Howton Chief Administrative Officer and Secretary |
Gabriel Brooks Chief Medical Officer | Jessie Hanrahan Chief Regulatory Officer | Jennifer Marlowe Chief Scientific Officer - Friedreich'��s Ataxia and Cardiac Pipeline |
Business Overview |
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid. |
Financial Overview |
For the fiscal year ended 31 December 2023, Solid Biosciences Inc revenues decreased from $8.1M to $0K. Net loss increased 12% to $96M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Gain on acquisition decrease from $18.2M (income) to $0K, General and administrative increase of 20% to $23.2M (expense). |
Employees: | 88 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $227.69M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$101.36M as of Dec 31, 2023 |
Net annual income (TTM): | -$96.02M as of Dec 31, 2023 |
Free cash flow (TTM): | -$95.70M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 37,756,877 as of Mar 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |